113 Shares in Amgen Inc. (NASDAQ:AMGN) Bought by Matrix Trust Co

Matrix Trust Co purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 113 shares of the medical research company’s stock, valued at approximately $36,000.

A number of other large investors have also recently bought and sold shares of the business. Nomura Holdings Inc. bought a new stake in shares of Amgen in the 4th quarter valued at $3,104,000. MGO One Seven LLC increased its stake in Amgen by 4.4% in the fourth quarter. MGO One Seven LLC now owns 6,363 shares of the medical research company’s stock valued at $1,833,000 after purchasing an additional 268 shares in the last quarter. Northwest Wealth Management LLC acquired a new position in shares of Amgen during the fourth quarter valued at about $242,000. Creative Planning boosted its position in shares of Amgen by 3.0% during the 4th quarter. Creative Planning now owns 162,429 shares of the medical research company’s stock worth $46,783,000 after purchasing an additional 4,720 shares in the last quarter. Finally, Vivaldi Capital Management LP grew its stake in shares of Amgen by 22.8% in the 4th quarter. Vivaldi Capital Management LP now owns 1,958 shares of the medical research company’s stock valued at $569,000 after buying an additional 363 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AMGN has been the topic of a number of research reports. Wells Fargo & Company downgraded Amgen from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $320.00 to $335.00 in a research note on Wednesday, August 7th. Cantor Fitzgerald assumed coverage on Amgen in a research report on Friday, September 27th. They set an “overweight” rating and a $405.00 target price on the stock. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $305.00 price target (down previously from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a report on Monday, September 16th. Finally, Morgan Stanley dropped their price objective on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 11th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Amgen has an average rating of “Moderate Buy” and a consensus target price of $326.30.

Amgen Stock Performance

Shares of NASDAQ:AMGN traded down $1.21 during midday trading on Thursday, reaching $321.20. The company had a trading volume of 331,718 shares, compared to its average volume of 2,466,670. The stock has a market cap of $172.30 billion, a P/E ratio of 46.06, a P/E/G ratio of 2.98 and a beta of 0.61. The company’s 50 day moving average price is $326.46 and its 200 day moving average price is $310.14. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. Amgen Inc. has a 52-week low of $249.70 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The company had revenue of $8.39 billion during the quarter, compared to analysts’ expectations of $8.35 billion. During the same quarter in the previous year, the firm earned $5.00 earnings per share. The firm’s revenue was up 20.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 2.80%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s dividend payout ratio is currently 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.